Table 2.
Biomarker groups | Group PIP | Individual biomarkers | Individual PIP | |
---|---|---|---|---|
Males | Serum PFAS | 0.65 | PFOA | 0.76 |
PFOS | 0.12 | |||
PFDA | 0.03 | |||
PFHxS | 0.06 | |||
PFNA | 0.03 | |||
High-molecular-weight urinary phthalate biomarkers | 0.79 | ∑DEHPb | 0.65 | |
MBzP | 0.22 | |||
MCOP | 0.02 | |||
MCNP | 0.06 | |||
MCPP | 0.05 | |||
Low-molecular-weight urinary phthalate biomarkers | 0.77 | MBP | 0.39 | |
MiBP | 0.58 | |||
MEP | 0.03 | |||
Females | Serum PFAS | 0.33 | PFOA | 0.26 |
PFOS | 0.10 | |||
PFDA | 0.17 | |||
PFHxS | 0.23 | |||
PFNA | 0.24 | |||
High-molecular-weight urinary phthalate biomarkers | 0.26 | ∑DEHPb | 0.19 | |
MCOP | 0.23 | |||
MCPP | 0.23 | |||
MBzP | 0.19 | |||
MCNP | 0.16 | |||
Low-molecular-weight urinary phthalate biomarkers | 0.36 | MBP | 0.28 | |
MiBP | 0.51 | |||
MEP | 0.21 |
Abbreviations: aBMD, areal bone mineral density; BKMR, Bayesian kernel machine regression; DEHP, di(2-ethylhexyl)phthalate; MBzP, mono-benzyl phthalate; MCNP, mono(carboxynonyl) phthalate; MCOP, mono(carboxyoctyl) phthalate; MCPP, mono-(3-carboxypropyl) phthalate; MEP, mono-ethyl phthalate; MIBP, mono-isobutyl phthalate; NHANES, National Health and Nutrition Examination Survey; PFDA, perfluorodecanoate; PFHxS, perfluorohexane sulfonate; PFNA, perfluorononanoate; PFOA, perfluorooctanoate; PFOS, perfluorooctane sulfonate; MBP, mono-n-butyl phthalate; PIP, posterior inclusion probability.
aPIPs indicate the relative contribution of individual or group biomarkers to the overall fit of the BKMR model. Models are adjusted for age, race/ethnicity, physical activity, indoor smoking by a household member, urinary creatinine concentrations, NHANES weights, and NHANES cycle.
bMolar sum of mono (2-ethylhexyl) phthalate, mono(2-ethyl-5-hydroxyhexyl) phthalate, mono(2-ethyl-5-oxohexyl) phthalate, and mono(2-ethyl-5-carboxypentyl) phthalate.